IL152872A0 - Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors - Google Patents

Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors

Info

Publication number
IL152872A0
IL152872A0 IL15287201A IL15287201A IL152872A0 IL 152872 A0 IL152872 A0 IL 152872A0 IL 15287201 A IL15287201 A IL 15287201A IL 15287201 A IL15287201 A IL 15287201A IL 152872 A0 IL152872 A0 IL 152872A0
Authority
IL
Israel
Prior art keywords
phosphodiesterase inhibitors
derivatives useful
pyrrolopyridinone derivatives
substituted
substituted pyrrolopyridinone
Prior art date
Application number
IL15287201A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL152872A0 publication Critical patent/IL152872A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15287201A 2000-05-17 2001-05-03 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors IL152872A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20464600P 2000-05-17 2000-05-17
PCT/US2001/014391 WO2001087882A2 (en) 2000-05-17 2001-05-03 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
IL152872A0 true IL152872A0 (en) 2003-06-24

Family

ID=22758822

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15287201A IL152872A0 (en) 2000-05-17 2001-05-03 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
IL152872A IL152872A (en) 2000-05-17 2002-11-15 Pyrolphyridinone derivatives are converted to use as phosphodiesterase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152872A IL152872A (en) 2000-05-17 2002-11-15 Pyrolphyridinone derivatives are converted to use as phosphodiesterase inhibitors

Country Status (29)

Country Link
US (3) US6635638B2 (es)
EP (1) EP1296981B1 (es)
JP (1) JP5366349B2 (es)
KR (2) KR100854050B1 (es)
CN (1) CN1280291C (es)
AR (1) AR028575A1 (es)
AT (1) ATE278690T1 (es)
AU (1) AU6117801A (es)
BG (1) BG65925B1 (es)
CA (1) CA2409743C (es)
CZ (1) CZ20023945A3 (es)
DE (1) DE60106252T2 (es)
ES (1) ES2230316T3 (es)
GE (1) GEP20053510B (es)
HK (1) HK1054034B (es)
HR (1) HRP20020911B1 (es)
HU (1) HUP0302226A3 (es)
IL (2) IL152872A0 (es)
MX (1) MXPA02011425A (es)
MY (1) MY126917A (es)
NO (1) NO324843B1 (es)
NZ (1) NZ522732A (es)
PL (1) PL363150A1 (es)
PT (1) PT1296981E (es)
RU (1) RU2267490C2 (es)
SK (1) SK286992B6 (es)
UA (1) UA72611C2 (es)
WO (1) WO2001087882A2 (es)
ZA (1) ZA200210114B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
ES2248412T3 (es) 2001-02-12 2006-03-16 Lilly Icos Llc Derivados de carbolina.
US7122554B2 (en) 2001-02-12 2006-10-17 Lilly Icos Llc. Carboline derivatives
DK1448562T3 (da) 2001-11-14 2007-09-24 Ortho Mcneil Pharmaceutical Co Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
AU2003243640A1 (en) * 2002-06-19 2004-01-06 Janssen Pharmaceutica, N.V. Substituted 2,4-dihydro-pyrrolo (3,4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
ZA200608176B (en) 2004-03-15 2008-05-28 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
JP2008531570A (ja) * 2005-02-25 2008-08-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ３−（ｒ）−３−（２，３−ジヒドロベンゾフラン−５−イル）−１，２，３，４−テトラヒドロピロロ［３，４−ｂ］キノリン−９−オンの有効かつ立体選択的大規模合成方法
US20070015798A1 (en) * 2005-02-25 2007-01-18 Xun Li Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
ES2632443T3 (es) 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
AU2015279047B2 (en) 2014-06-27 2020-01-02 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
CN108752340B (zh) * 2018-07-18 2020-09-01 山东中医药大学附属医院 吡咯并喹啉衍生物及其在治疗心律失常中的用途
CN109134463B (zh) * 2018-09-17 2020-05-08 山东大学 β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US204646A (en) * 1878-06-04 Improvement in hat-brims
DE2023514A1 (de) 1970-05-14 1971-12-02 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 5,6-gamma-Pyridonderivaten
CH625521A5 (es) 1976-10-15 1981-09-30 Sandoz Ag
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
CA2189053A1 (en) 1994-04-29 1995-11-09 Shigenori Ohkawa Condensed heterocyclic compounds, their production and use as gnrh antagonists
DE4436509A1 (de) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
CA2213510A1 (en) 1995-06-01 1996-12-05 Takeda Chemical Industries, Ltd. Diazepinones, their production and use
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2792937B1 (fr) * 1999-04-27 2001-08-10 Cemaf NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази

Also Published As

Publication number Publication date
NO324843B1 (no) 2007-12-17
IL152872A (en) 2010-11-30
BG65925B1 (bg) 2010-05-31
HK1054034B (zh) 2005-04-29
KR100854050B1 (ko) 2008-08-26
JP5366349B2 (ja) 2013-12-11
JP2003533524A (ja) 2003-11-11
DE60106252D1 (de) 2004-11-11
AU6117801A (en) 2001-11-26
US20040044021A1 (en) 2004-03-04
CA2409743A1 (en) 2001-11-22
NZ522732A (en) 2004-10-29
KR20030031483A (ko) 2003-04-21
BG107284A (bg) 2003-07-31
PL363150A1 (en) 2004-11-15
US20020010183A1 (en) 2002-01-24
SK286992B6 (sk) 2009-09-07
WO2001087882A2 (en) 2001-11-22
CN1280291C (zh) 2006-10-18
HUP0302226A3 (en) 2012-12-28
US6818646B2 (en) 2004-11-16
ES2230316T3 (es) 2005-05-01
AR028575A1 (es) 2003-05-14
US20050113402A1 (en) 2005-05-26
NO20025525D0 (no) 2002-11-18
PT1296981E (pt) 2004-12-31
ATE278690T1 (de) 2004-10-15
NO20025525L (no) 2003-01-03
CA2409743C (en) 2010-10-19
US6635638B2 (en) 2003-10-21
MXPA02011425A (es) 2004-09-06
GEP20053510B (en) 2005-05-10
DE60106252T2 (de) 2006-03-02
MY126917A (en) 2006-10-31
HRP20020911A2 (en) 2004-12-31
CN1441801A (zh) 2003-09-10
CZ20023945A3 (cs) 2003-10-15
HRP20020911B1 (en) 2009-01-31
SK17132002A3 (sk) 2003-12-02
HK1054034A1 (en) 2003-11-14
RU2267490C2 (ru) 2006-01-10
KR20020094063A (ko) 2002-12-16
EP1296981A2 (en) 2003-04-02
EP1296981B1 (en) 2004-10-06
ZA200210114B (en) 2004-03-12
UA72611C2 (uk) 2005-03-15
HUP0302226A2 (hu) 2003-11-28
WO2001087882A3 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
HK1066546A1 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
IL154839A0 (en) Xanthine phosphodiesterase v inhibitors
AU6116701A (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
IL153484A0 (en) Colchinol derivatives as angiogenesis inhibitors
AU6623201A (en) Colchinol derivatives as angiogenesis inhibitors
AU5741301A (en) Arylmethylamine derivatives for use as tryptase inhibitors
HUP0202713A3 (en) Pteridinones as kinase inhibitors
IL156958A0 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
PL355099A1 (en) Pyrrole derivatives as phosphodiesterase vii inhibitors
AU2954102A (en) (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
PL355022A1 (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors
PL351822A1 (en) Thienopyrimidines as phosphodiesterase inhibitors
AU2002224835A1 (en) Dihydroisoquinolines as novel phosphodiesterase inhibitors
AU2001271948A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
AU2002348365A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
SI1226143T1 (en) Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
SI1289985T1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
AU2002317788A1 (en) Imidazotriazines for use as phosphodiesterase inhibitors